Bifidobacterium lactis BL-99 modulates intestinal inflammation and functions in zebrafish models.

Abstract

This study was designed to explore the therapeutics and the mechanisms of a patented and marked gastric acid and intestine juice-resistant probiotics Bifidobacterium lactis BL-99 (B. lactis BL-99) on the intestinal inflammation and functions in the zebrafish models. After feeding for 6 hours, B. lactis BL-99 was fully retained in the larval zebrafish intestinal tract and stayed for over 24 hours. B. lactis BL-99 promoted the intestinal motility and effectively alleviated aluminum sulfate-induced larval zebrafish constipation (p < 0.01). Irregular high glucose diet induced adult zebrafish intestinal functional and metabolic disorders. After fed with B. lactis BL-99, IL-1β gene expression was significantly down-regulated, and IL-10 and IL-12 gene levels were markedly up-regulated in this model (p < 0.05). The intestinal lipase activity was elevated in the adult zebrafish intestinal functional disorder model after B. lactis BL-99 treatment (p < 0.05), but tryptase content had no statistical changes (p > 0.05). B. lactis BL-99 improved the histopathology of the adult zebrafish intestinal inflammation, increased the goblet cell numbers, and up-and-down metabolites were markedly recovered after treatment of B. lactis BL-99 (p < 0.05). These results suggest that B. lactis BL-99 could relieve intestinal inflammation and promote intestinal functions, at least in part, through modulating intestinal and microbial metabolism to maintain intestinal health.

• Authors: Meng Chen, Chinfeng Liu, Mingzhu Dai, Qinwen Wang, Chunqi Li, Weilian Hung
• Journal: PloS one (PLoS One) Vol. 17 Issue 2 Pg. e0262942 ( 2022) ISSN: 1932-6203 [Electronic] United States
• PMID: 35171916 (Publication Type: Journal Article)

Chemical References

• Alum Compounds
• Interleukin-1beta
• Interleukin-10
• aluminum sulfate
• Glucose

Topics

• Alum Compounds (toxicity)
• Animals
• Bifidobacterium (physiology)
• Constipation (chemically induced, pathology, therapy)
• Discriminant Analysis
• Disease Models, Animal
• Down-Regulation (drug effects)
• Gastrointestinal Motility (drug effects)
• Glucose (pharmacology)
• Inflammation (chemically induced, pathology, therapy)
• Interleukin-10 (genetics, metabolism)
• Interleukin-1beta (genetics, metabolism)
• Intestines (metabolism, microbiology, pathology)
• Larva (drug effects, metabolism)
• Probiotics (pharmacology, therapeutic use)
• Up-Regulation (drug effects)
• Zebrafish (growth & development)